B Cell Maturation Antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17),is encoded by TNFRSF17 gene in human. It is a transmembrane signaling protein preferentially expressed on plasma cells. It is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF). Its ligands including BAFF and A Proliferation Inducing Ligand (APRIL). BCMA is involved in JNK and NF-kB activation pathways that induce B-cell development and autoimmune responses. BCMA has been implicated in autoimmune disorders as well as B-lymphocyte malignancies, leukemia, lymphomas, and multiple myeloma.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE